Enlivex Therapeutics Ltd. (ENLV)
| Market Cap | 141.24M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -9.38M |
| Shares Out | 8.65M |
| EPS (ttm) | -0.74 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $10.49 |
| Previous Close | $10.29 |
| Change ($) | 0.20 |
| Change (%) | 1.94% |
| Day's Open | 10.23 |
| Day's Range | 10.15 - 10.55 |
| Day's Volume | 61,505 |
| 52-Week Range | 3.77 - 14.50 |
Nes Ziona, Israel, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced ...
Enlivex Announces Pre-Print Publication of Full Results from Phase Ib Severe Sepsis Trial on medRxiv
– Comparison of 10 AllocetraTM-treated patients with 37 matched controls showed significant positive responses in state of organ failure, duration of ICU stay and mortality in a highly fragile...
Nes Ziona, Israel, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive interim results of...
* Significant short and long-term clinical improvement for a hospitalized patient with a rare disease that currently has no effective treatment options *
* Dr. Schwartz Served as ArQule's Chief Medical Officer and Head of Research and Development Prior to the $2.7 billion Acquisition of ArQule by Merck in February 2020 *
Nes Ziona, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that it will present the c...
Nes-Ziona, Israel, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today announced that the U.S. Patent and T...
Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.
Nes Ziona, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry o...
Nes Ziona, Israel, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the first two patients...
Nes Ziona, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported that the Israeli Ministry o...
Shares of Enlivex Therapeutics Ltd (NASDAQ: ENLV) broke out of a $4-$6 trading range last week and have been seeing strong upward momentum ever since. A Rally On COVID-19 Data: The catalyst b...
Enlivex just announced that it will launch Phase 2 trials for a plasma-based coronavirus treatment, and ENLV stock is soaring in response. The post ENLV Stock: Why Enlivex Is Soaring 70% Today...
Nes Ziona, Israel, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage immunotherapy company, today reported positive top-line results o...
Nes-Ziona, Israel, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the China National Intellectual Property Adminis...
Nes-Ziona, Israel, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd., a clinical-stage immunotherapy company, today announced that the U.S. Patent and Trademark Office issued a no...
- D ata show a 90% decrease in mortality with AllocetraTM treatment in a murine cecal ligation and puncture severe sepsis model
Nes-Ziona, Israel, June 18, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Japan Patent Office (JPO) has issued a notic...
Nes Ziona, Israel, June 01, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that management will present a corporat...
Nes Ziona, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that an investigator-initiated multi-cen...
Nes Ziona, Israel, April 13, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the Israel Innovation Authority ...
– Final Analysis Comparing 10 AllocetraTM-Treated Patients with 37 Matched Controls Showed Significant Positive Responses in State of Organ Failure, ICU Hospitalization and Mortality in a High...
Nes-Ziona, March 09, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israel Patent Office granted a new patent (#239236)...
Nes-Ziona, Israel, March 05, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announce...
Regarding Submission of Proposal to the Korean Authorities for Potential Use of Allocetra TM as Treatment of Patients with Coronavirus Disease (COVID-19) Patients Admitted to ICU
Nes-Ziona, Israel, March 02, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive ag...
Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced...
Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agr...
Shares of Israel-based Enlivex Therapeutics Ltd. ENLV, +4.90% rocketed 53% in active premarket trading Monday, after the clinical-stage immunotherapy company said it has started a plan to incr...
Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increa...
Nes-Ziona, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a s...
About ENLV
Enlivex Therapeutics, a clinical stage immunotherapy company, engages in developing allogeneic drugs for immune system rebalancing. Its product candidate is Allocetra, an immunotherapy candidate, which is in Phase IIb clinical trial in patients with severe sepsis; that is in investigator-initiated Phase II clinical trial for the treatment of COVID-19 patients in severe and critical conditions; and which is in Phase IIa clinical trial for the prevention of Graft Versus Host Disease in allogeneic hematopoietic stem cell transplants (HSCT) patient... [Read more...]
| Industry Biotechnology | IPO Date Dec 12, 1995 |
| CEO Oren Hershkovitz | Employees 36 |
| Stock Exchange NASDAQ | Ticker Symbol ENLV |
Analyst Forecasts
According to one analyst, the rating for ENLV stock is "Buy" and the 12-month stock price forecast is 22.00.